2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

SUDHL4 cells

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15322
    PRT062607
    4 Publications Verification

    P505-15; PRT-2607; BIIB-057

    		 Syk Apoptosis Caspase Inflammation/Immunology Cancer
    PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC50 value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .
    PRT062607
  • HY-158421
    MS-L6

    		Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    MS-L6 is a potent inhibitor of oxidative phosphorylation (OXPHOS) that can acts as electron transport chain complexes I (ETC-I) combining inhibition of NADH oxidation and uncoupling effect .
    MS-L6
  • HY-178683
    ALV-05-077-01

    		Others Cancer
    ALV-05-077-01 is a BLC6/BLC6B degrader. ALV-05-077-01 depletes endogenous BCL6 levels in SuDHL4 cells (high BCL6 expression) and BCL6B levels in KYO1 cells (high BCL6B expression). ALV-05-077-01 can be used for the study of hematological malignancies .
    ALV-05-077-01
  • HY-178700
    ALV-05-151-02

    		Others Cancer
    ALV-05-151-02 is a BLC6/BLC6B degrader. ALV-05-151-02 depletes endogenous BCL6 levels in SuDHL4 cells (high BCL6 expression) and BCL6B levels in KYO1 cells (high BCL6B expression). ALV-05-151-02 can be used for the study of hematological malignancies .
    ALV-05-151-02
  • HY-172375
    E3 Ligase Ligand-linker Conjugate 170

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 170 (Compound I) exhibits anti-proliferative activity in non-Hodgkin's lymphoma cell SU-DHL-4 with IC50 < 0.2 μM. E3 Ligase Ligand-linker Conjugate 170 is the conjugate composed of an E3 ligase ligand and a linker that can be used for PROTAC synthesis .
    E3 Ligase Ligand-linker Conjugate 170
  • HY-148640
    WK500B

    		BCL6 MDM-2/p53 Histone Methyltransferase CXCR Apoptosis Cancer
    WK500B is a potent and orally active BCL6 inhibitor with a KD of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL) .
    WK500B

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: